02.25.2013

On February 11th and 12th, hundreds of institutional investors, industry analysts, and senior biotechnology executives gathered in New York for BIO's 15th annual CEO & Investor Conference, the largest investor conference focused on established and emerging publicly traded and select private biotech companies. In this special edition of the BIO Newsletter, we showcase some of the event highlights.

CONFERENCE SPECIAL REPORT

The BIO CEO & Investor Conference

Over 1,200 industry leaders were in attendance this year, and BIO facilitated hundreds of One-on-One Partnering meetings that provided an opportunity for investors and companies to connect. This special report showcases some of the highlights of the conference...

FIRESIDE CHAT

Celgene CEO on New Multiple Myeloma Drug Approvals

Following on the heels of two big announcements in February, Celgene CEO Robert Hugin participated in a fireside chat with Joel Sendek...

FIRESIDE CHAT

Onyx CEO One of 25 Most Influential People in Biopharm

Coles contributes a majority of Onyx's success to two things: a strong mix of collaborations which has allowed business to move rapidly and the continued effort to remain opportunistic...

PANEL DISCUSSION

Orphan Drugs: Making Rare Disease Rarer

The signing of FDASIA by President Obama in July reinforces the country's commitment to fostering innovation for rare diseases...

FIRESIDE CHAT

Despite Low Funding, Biotech Productivity Remains High

John Milligan, President and COO of Gilead Sciences, spoke in a standing room only fireside chat with Joel Sendek...

FIRESIDE CHAT

Jean-Jacques Bienaimé, Chief Executive Officer, BioMarin

Under his leadership, the market capitalization of BioMarin went from around $450 million in May 2005 to over $4.5 billion in the summer of 2012...

CLOSING PLENARY

Tales From the Wild West (Wing)

The election chips have fallen and the country is gearing up for another four years of economic challenges and political wrangling. With divided government, compromises will be difficult and time consuming to reach...

IPOs

The IPO Road Less Traveled: Form 10

When investors talk about alternate exits for private companies beyond the traditional IPO they are usually referring to reverse mergers, if not outright acquisitions...

PARTNERSHIPS

Putting a Ring on It: Advice on Successful Drug Development Collaborations

Drug development partnerships can look lucrative to small biotechs eager to monetize their discoveries, but, like any relationship, these tie-ups take work and both parties run the risk of ending up in tears...

CHINA

Small Biotech Companies and China: 5 Keys to Success

Big pharmaceutical countries aren't the only ones investing in China. Emerging and mid-sized biotech companies are also exploring ways to enter China's lucrative market and maximize their investment in the country...

PATENT CLIFF

How to Survive the Patent Cliff: Eli Lilly's CEO at the BIO CEO & Investor Conference

Like a number of companies, Eli Lilly is confronting a wave of patent expirations called the patent cliff...

BIOTECH STOCKS

Word on the Street – Biotech Stocks Only Have Room to Go Up

The Opening Lunch Plenary at this year's BIO CEO & Investor Conference was a lively discussion between portfolio managers and senior buy-side analysts...

UPCOMING EVENTS

10.08.13

BIO Investor Forum

The BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies...

Save the Date

03.11.13

BIO-Europe Spring

BIO-Europe Spring® is the springtime counterpart to EBD Group's flagship conference, BIO-Europe®, and continues the tradition of providing life science companies with high caliber partnering opportunities...

04.19.13

BIO Executive Training Programs

The Business Development Basics and Advanced Business Development courses support the activity that takes place at our partnering, investor and venture capital conferences...

04.22.13

2013 BIO International Convention

65 countries. 16,500 leaders. Countless partnering opportunities. Join 25,000+ face-to-face meetings between senior-level representatives from 3,000+ companies...

05.22.13

Bio€quity Europe

Bio€quity Europe is the seminal industry event for financial dealmakers looking for investor-validated life science companies positioning themselves to attract capital, and for pharmaceutical licensing professionals to assess top prospects...

November 2013

BIO Convention in China

The BIO Convention in China brings together executives from biotechnology, pharmaceutical companies and investment firms from North America, Europe and Asia to meet and explore business opportunities with China's emerging biotech sector...

SAVE THE DATE

ON Twitter.COM/#BIOCEO13

How can a company survive the patent cliff? Eli Lilly's (@Lilly_COI) CEO at #BIOCEO13 ow.ly/hEt85 — @IamBiotech

5 Retweets

Glad to join Josh Bolten at #BIOCEO13 to talk tax policy, health reform, & prepping the #sotu with Presidents Clinton & Bush cc @IAmBiotech — @johnpodesta

2 Retweets

Kudos BD team! @bio1x1 "#BIOCEO13 stats: overall attendance up 15%, investors up 28%! Also had more 1x1 mtngs: 1387 total" — @Kspits

1 Retweet

Biotech investor enthusiasm moves from risk-reduced generic reformulation models to focus on innovation #BIOCEO13 — @BioWorld

7 Retweets

@ceels66 panels and chats were high points of #BIOCEO13. Also psyched to see so many private company presentations so well attended. — @chriserdman

2 Retweets